晚期头颈部鳞癌的内科治疗教材.pptVIP

- ERBITUX monotherapy led to improved efficacy compared with various other second-line therapies. - ERBITUX monotherapy was associated with a response rate of 13% compared with 3% for all patients in the retrospective study. This effect was even more pronounced when the results with ERBITUX monotherapy were compared with those for a sub-group of patients in the retrospective study who received various second-line chemotherapy regimens, none of whom responded to treatment. - The disease control rate achieved with ERBITUX monotherapy was also considerably higher than that seen in the retrospective study (46% versus 15%). - ERBITUX monotherapy demonstrated an overall survival of 5.9 months, which is outstanding for this population of patients. - The overall survival achieved with ERBITUX represented an absolute increase of 2.5 months in overall survival compared with the retrospective study. - Interestingly, as shown by the data from the other two prospective ERBITUX studies, the efficacy, in terms of both response and survival, achieved with ERBITUX monotherapy was not improved by the reinclusion of platinum in the regimen. 1. Vermorken JB, Bourhis J, Trigo J, et al. J Clin Oncol 2005;23(16S):Abstract 5505. Virtual presentation: 泰欣生?治疗头颈部鳞癌 76例Ⅲ、Ⅳa 头颈癌患者 放疗＋化疗(Cisplatin) ＋泰欣生 （200mg） n=20 放疗(60-66 Gy) ，n=19 放疗＋化疗(Cisplatin)，n=20 放疗＋泰欣生（200mg），n=17 B.K. Reddy, et al. ASTRO 2007 随机分组 疗后第24周 响应 RT (n=19) RT +泰欣生 (n=17) P值 患者数（例） % 患者数（例） % CR 6 31.58 12 70.59 0.044 PR 1 5.26 1 5.88 1.000 SD 1 5.26 - - 1.000 PD 11 57.89 4 23.53 0.049 OR 7 36.84% 13 76.47 0.023 RT组客观疗效分析 B.K. Reddy, et al. ASTRO 2007 疗后第24周 响应 RT +CT (n=20) CT+RT +泰欣生 (n=20) P值 患者数（例） % 患者数（例） % CR 14 70 18 90 0.375 PR 0 0 2 10 0.489 SD - - - - - PD 6 30 0 0 0.033 OR 14 70 20 100.00 0.020 CT+RT组客观疗效分析 B.K. Reddy, et al. ASTRO 2007 总生存率获益情况 组别 生存率（%） RT 57.9 RT ＋泰欣生 64.7 RT ＋ CT 70 RT ＋ CT ＋泰欣生 95 15个月生存率 B.K. Reddy, et al. ASTRO 2007 中位生存时间（RT/RT+Nimo） RT: MST